DOXORUBICIN News

DOXORUBICIN currently has 8 news articles, with 60 predicted indications.

This page combines the AI-predicted indications for DOXORUBICIN with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (60):
- Wilms tumor (99.0%)
- primary cutaneous diffuse large B-cell lymphoma, Leg type (99.0%)
- hereditary site-specific ovarian cancer syndrome (99.0%)
- diffuse large B-cell lymphoma (99.0%)
- Hodgkins lymphoma (99.0%)
- breast neoplasm (99.0%)
- malignant Sertoli-Leydig cell tumor of ovary (99.0%)
- ovarian mucinous adenocarcinoma (99.0%)
- familial thyroid carcinoma (99.0%)
- lymphoma (99.0%)
- immature ovarian teratoma (99.0%)
- ovarian small cell carcinoma (99.0%)
- ALK-positive large B-cell lymphoma (99.0%)
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (99.0%)
- primary mediastinal large B-cell lymphoma (99.0%)
- Hodgkin's paragranuloma (99.0%)
- diffuse large B-cell lymphoma of the central nervous system (99.0%)
- primary central nervous system lymphoma (99.0%)
- small cell lung carcinoma (99.0%)
- myeloid leukemia (99.0%)
- familial papillary thyroid carcinoma with renal papillary neoplasia (99.0%)
- mantle cell lymphoma (99.0%)
- T-cell/histiocyte rich large B cell lymphoma (99.0%)
- therapy related acute myeloid leukemia and myelodysplastic syndrome (99.0%)
- differentiated thyroid carcinoma (99.0%)
- acute myeloid leukemia with CEBPA somatic mutations (99.0%)
- precursor T-cell acute lymphoblastic leukemia (99.0%)
- non-Hodgkin lymphoma (99.0%)
- Burkitt lymphoma (99.0%)
- malignant non-dysgerminomatous germ cell tumor of ovary (99.0%)
- Langerhans cell histiocytosis (99.0%)
- ovarian clear cell adenocarcinoma (99.0%)
- familial papillary or follicular thyroid carcinoma (99.0%)
- kidney Wilms tumor (99.0%)
- inherited acute myeloid leukemia (99.0%)
- obsolete Hodgkin's granuloma (99.0%)
- ovarian endometrioid adenocarcinoma (99.0%)
- classic Hodgkin lymphoma, lymphocyte-rich type (99.0%)
- acute lymphoblastic leukemia (disease) (99.0%)
- B-cell neoplasm (99.0%)
- primary non-gestational choriocarcinoma of ovary (99.0%)
- acute myeloid leukemia with t(8;16)(p11;p13) translocation (99.0%)
- acute myeloid leukemia with t(6;9)(p23;q34) (99.0%)
- lung cancer (99.0%)
- yolk sac tumor (99.0%)
- ovarian carcinosarcoma (99.0%)
- intravascular large B-cell lymphoma (99.0%)
- familial ovarian cancer (99.0%)
- classic Hodgkin lymphoma (99.0%)
- acute myeloid leukemia with t(8;21)(q22;q22) translocation (99.0%)
- Ewing sarcoma (99.9%)
- well-differentiated fetal adenocarcinoma of the lung (99.9%)
- primary pulmonary lymphoma (99.8%)
- pulmonary blastoma (99.8%)
- chronic myelogenous leukemia, BCR-ABL1 positive (99.8%)
- monocytic leukemia (99.7%)
- botryoid-type embryonal rhabdomyosarcoma of the vagina (99.7%)
- parameningeal embryonal rhabdomyosarcoma (99.7%)
- rhabdomyosarcoma (disease) (99.7%)
- ganglioneuroblastoma (disease) (99.7%)